ASCO 2017 - NHL: 82% ORR with axicabtagene ciloleucel in phase 1/2 ZUMA-1 trial
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Axi-cel (axicabtagene ciloleucel; KTE-C19) induced an objective response rate (ORR) of 82% in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL) in this phase 1/2 trial, and the response is ongoing in 44% of patients almost 9 mo later.
Why this matters
Outcomes are poor in activated B-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL) and r-NHL.
ZUMA-1 is the first multicenter trial of anti-CD19 chimeric antigen receptor (CAR) T cells, axi-cel, in r-NHL.
Single-arm, open-label, multicenter, phase 1/2 study to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 CAR-positive T-cell therapy, in r-NHL.
Funding: Kite Pharma, Inc. and the Leukemia & Lymphoma Society.